SummaryIntravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor reveals how the tumor microenvironment affects response to BRAF inhibition by PLX4720. Initially, melanoma cells respond to PLX4720, but rapid reactivation of ERK/MAPK is observed in areas of high stromal density. This is linked to “paradoxical” activation of melanoma-associated fibroblasts by PLX4720 and the promotion of matrix production and remodeling leading to elevated integrin β1/FAK/Src signaling in melanoma cells. Fibronectin-rich matrices with 3–12 kPa elastic modulus are sufficient to provide PLX4720 tolerance. Co-inhibition of BRAF and FAK abolished ERK reactivation and led to more effective control of BRAF-mutant melanoma. We propose that pa...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
Perhaps the most pressing need in cancer therapeutics is to understand drug resistance. In this issu...
Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis incl...
Approximately half of all melanoma patients harbour activating mutations in the serine/threonine kin...
Approximately half of all melanoma patients harbour activating mutations in the serine/threonine kin...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
Very few cancer patients are cured through drug therapy alone, with the majority exhibiting acquired...
Very few cancer patients are cured through drug therapy alone, with the majority exhibiting acquired...
Very few cancer patients are cured through drug therapy alone, with the majority exhibiting acquired...
Several mechanisms of resistance to inhibition of BRAF activity in melanoma cells have been describe...
SummaryCombined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy but is s...
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRA...
BRAF (v-raf murine sarcoma viral oncogene homolog B) inhibitors elicit a transient anti-tumor respon...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
SummaryDespite the development of potent RAF/mitogen-activated protein kinase (MAPK) pathway inhibit...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
Perhaps the most pressing need in cancer therapeutics is to understand drug resistance. In this issu...
Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis incl...
Approximately half of all melanoma patients harbour activating mutations in the serine/threonine kin...
Approximately half of all melanoma patients harbour activating mutations in the serine/threonine kin...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
Very few cancer patients are cured through drug therapy alone, with the majority exhibiting acquired...
Very few cancer patients are cured through drug therapy alone, with the majority exhibiting acquired...
Very few cancer patients are cured through drug therapy alone, with the majority exhibiting acquired...
Several mechanisms of resistance to inhibition of BRAF activity in melanoma cells have been describe...
SummaryCombined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy but is s...
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRA...
BRAF (v-raf murine sarcoma viral oncogene homolog B) inhibitors elicit a transient anti-tumor respon...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
SummaryDespite the development of potent RAF/mitogen-activated protein kinase (MAPK) pathway inhibit...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
Perhaps the most pressing need in cancer therapeutics is to understand drug resistance. In this issu...
Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis incl...